AIPG Ai Technology Group Inc. - 8-K/A

Item 1.01 – Entry into a Material Definitive Agreement

On December 15, 2025, AI Technology Group Inc. (the “Corporation”) entered into a Share Exchange Agreement as amended hereto with AVM Biotechnology Inc. , a Nevada corporation (“AVMN”), and Biomed 360 Solutions Corp. , a British Columbia corporation (“Biomed 360”), the sole shareholder of AVMN.

Under the terms of the agreement, the Corporation agreed to acquire 100% of the issued and outstanding shares of AVMN in exchange for 100 common shares of the Corporation . As a result, AVMN became a wholly-owned subsidiary of the Corporation.

The transaction is intended to qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code of 1986, as amended.

Item 2.01 – Completion of Acquisition or Disposition of Assets

On December 15, 2025, the Corporation completed the acquisition of AVMN.

·

Consideration: 100 common shares of the Corporation issued to Biomed 360 in exchange for 100 common shares of AVM.

·

Result: AVMN is now a wholly-owned subsidiary of the Corporation.

·

Convertible Debentures: On December 15, 2025, AVMN had outstanding convertible debentures totaling $1,587,000, convertible into 634,800 common shares of the Corporation. These debentures will be converted into common shares of the Corporation pursuant to the Share Exchange Agreement.

Item 3.02 – Unregistered Sales of Equity Securities

The shares issued in connection with the acquisition were not registered under the Securities Act of 1933 and are considered restricted securities under Rule 144. The issuance was made in reliance upon exemptions from registration provided by Section 4(a)(2) of the Securities Act.

Item 9.01 – Financial Statements and Exhibits

·

(a) Financial Statements of Business Acquired: The financial statements of AVMN required by Rule 3-05 of Regulation S-X will be filed by amendment to this Form 8-K within 71 calendar days after the date this initial report is filed.

·

(b) Pro Forma Financial Information: Pro forma financial information required by Article 11 of Regulation S-X will be filed by amendment within 71 calendar days.

·

(d) Exhibits:

○

Exhibit 10.1 – Amended Share Exchange Agreement dated December 15, 2025, among AI Technology Group Inc., AVM Biotechnology Inc., and Biomed 360 Solutions Corp.

○

Exhibit 101 – Cover Page Data File (embedded within the Inline XBRL document)

2